This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Law and Medicine  • Statistics and Research Methods  • Transplantation  • Transplantation, Other  • Alert me on articles by topic

Mike Mitka

JAMA. 2006;296:1720.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Sen Tom Harkin (D, Iowa) said Congress must overcome President Bush's July veto of HR 810, the Stem Cell Research Enhancement Act, which would make available multiple stem cell lines permissible for use in federally funded medical research.

Harkin's comments came during a September 6 Senate Appropriations Subcommittee on Labor, Health and Human Services and Education hearing on controversies surrounding stem cell research. At center stage was testimony surrounding Advanced Cell Technology (ACT) Inc of Worcester, Mass, and its findings published online ahead of print in Nature (Klimanskaya I et al. Nature. August 23, 2006. doi: 10.1038/nature05142) describing a technique for developing stem cell lines from individual blastomeres without destroying the embryo.

Harkin said that ACT should have made it clearer that what was described was more theoretical than real, as none of the embryos discussed in the Nature report survived. Harkin, who plans to reintroduce legislation . . . [Full Text of this Article]